PortadaGruposCharlasMásPanorama actual
Buscar en el sitio
Este sitio utiliza cookies para ofrecer nuestros servicios, mejorar el rendimiento, análisis y (si no estás registrado) publicidad. Al usar LibraryThing reconoces que has leído y comprendido nuestros términos de servicio y política de privacidad. El uso del sitio y de los servicios está sujeto a estas políticas y términos.

Resultados de Google Books

Pulse en una miniatura para ir a Google Books.

Cargando...

The Billion Dollar Molecule: One Company's Quest for the Perfect Drug

por Barry Werth

MiembrosReseñasPopularidadValoración promediaMenciones
1563175,686 (4.07)3
Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing -- atom by atom -- both a new life-saving immunosuppressant drug, and a drug to combat the virus that causes AIDS. You will be hooked from start to finish, as you go from the labs, where obsessive, fiercely competitive scientists struggle for a breakthrough, to Wall Street, where the wheeling and dealing takes on a life of its own, as Boger courts investors and finally decides to take Vertex public. Here is a fascinating no-holds-barred account of the business of science, which includes an updated epilogue about the most recent developments in the quest for a drug to cure AIDS.… (más)
Cargando...

Inscríbete en LibraryThing para averiguar si este libro te gustará.

Actualmente no hay Conversaciones sobre este libro.

» Ver también 3 menciones

Mostrando 3 de 3
Way too much nitty gritty detail for a lay reader. If you were involved in this company or a scientist you might enjoy it more than I did. ( )
  BrendaRT20 | Sep 3, 2023 |
Werth's book about a company's inception and its revolutionary use of rational drug design should be required reading for all in the sciences. It highlights to amazing extents the pros and cons of academia and industry, and as a current PhD student, I can fully relate to the issues. The scientific struggles of publishing and politics are all excruciatingly detailed, and you're left in awe of the immense strength and will of the characters. Werth's prose is riveting as well. I wish there were a more recent book of equal calibre, detailing maybe a company's trials in genomic medicine. ( )
  bsmashers | Aug 1, 2020 |
A very interesting story of a pharmaceutical startup. So much hype, with no solid basis, and yet they survive. Werth does a good job explaining the business, the science, and the experience of doing the science.

> Scientists, unlike, say, athletes, conjure their own competition. They seldom know precisely whom they’re competing with or where they are in the race. They hear things—rumors, reports—but the information comes at a distance and with a price: It may be exaggerated, deliberately misleading, or simply false. The atmosphere in a lab in the throes of a heated project is insular, secretive, xenophobic, superheated, and paranoid.

> "There's two situations where you want to be aggressive about publishing. One is when you're behind; the other is when you're ahead. When you're ahead, you demoralize the other guy. When you're behind, you have nothing to lose. It's when you don't know that you want to be most careful." ( )
  breic | Aug 2, 2019 |
Mostrando 3 de 3
sin reseñas | añadir una reseña
Debes iniciar sesión para editar los datos de Conocimiento Común.
Para más ayuda, consulta la página de ayuda de Conocimiento Común.
Título canónico
Título original
Títulos alternativos
Fecha de publicación original
Personas/Personajes
Lugares importantes
Acontecimientos importantes
Películas relacionadas
Epígrafe
Dedicatoria
Primeras palabras
Información procedente del conocimiento común inglés. Edita para encontrar en tu idioma.
Squatting between the twin towers of the World Trade Center in New York City, the Vista International Hotel is a minor cultural monument of the 1980s.
Citas
Últimas palabras
Información procedente del conocimiento común inglés. Edita para encontrar en tu idioma.
(Haz clic para mostrar. Atención: puede contener spoilers.)
Aviso de desambiguación
Editores de la editorial
Blurbistas
Idioma original
DDC/MDS Canónico
LCC canónico

Referencias a esta obra en fuentes externas.

Wikipedia en inglés (2)

Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing -- atom by atom -- both a new life-saving immunosuppressant drug, and a drug to combat the virus that causes AIDS. You will be hooked from start to finish, as you go from the labs, where obsessive, fiercely competitive scientists struggle for a breakthrough, to Wall Street, where the wheeling and dealing takes on a life of its own, as Boger courts investors and finally decides to take Vertex public. Here is a fascinating no-holds-barred account of the business of science, which includes an updated epilogue about the most recent developments in the quest for a drug to cure AIDS.

No se han encontrado descripciones de biblioteca.

Descripción del libro
Resumen Haiku

Debates activos

Ninguno

Cubiertas populares

Enlaces rápidos

Valoración

Promedio: (4.07)
0.5
1
1.5
2 1
2.5 1
3
3.5 1
4 7
4.5
5 5

¿Eres tú?

Conviértete en un Autor de LibraryThing.

 

Acerca de | Contactar | LibraryThing.com | Privacidad/Condiciones | Ayuda/Preguntas frecuentes | Blog | Tienda | APIs | TinyCat | Bibliotecas heredadas | Primeros reseñadores | Conocimiento común | 205,514,912 libros! | Barra superior: Siempre visible